Schedule 13D ownership disclosure
Benitec Biopharma Inc
Common Stock, par value $0.0001 · CUSIP: 08205P209
Event date: 2025-11-07
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SUVRETTA CAPITAL MANAGEMENT, LLCReported CIK 0001569064
Shares: 17,761,945 · Class: 44.1%
- Averill Master Fund, Ltd.Reported CIK 0001939329
Shares: 15,237,643 · Class: 37.8%
- Averill Madison Master Fund, Ltd.Reported CIK 0002021243
Shares: 2,524,302 · Class: 6.3%
- Aaron Cowen
Shares: 17,761,945 · Class: 44.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000899140-25-001257
- Form type
- SCHEDULE 13D/A
- Filer
- Benitec Biopharma Inc.
- CIK
- CIK 1808898
- Filed
- Nov 10, 2025
- Reporting period
- Nov 07, 2025
- Description
- Schedule 13D beneficial ownership